Obesity Trial, Recruiting NCT05125822 Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago Condition: Obesity
Back to Obesity

Obesity Trial, Recruiting

NCT05125822
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 11 and under 16 years old
  • People with a BMI above 30 kg/m² or at or above the 95th percentile for BMI (a measure used to assess body weight relative to height and age)
  • People at a mid-stage of puberty development, known as Tanner stage 2, 3, or 4 (confirm with trial site for clarification on what stage applies)

Who may not be able to join:

  • People at the earliest or latest stage of puberty development (Tanner stage 1 or 5)
  • People who have previously had weight-loss (bariatric) surgery
  • People who have used certain weight-loss medications in the last 3 months, including orlistat, metformin, phentermine, topiramate, liraglutide, or a combination of naltrexone/bupropion (note: taking naltrexone or bupropion alone does not disqualify someone)
  • People whose obesity is caused by a specific genetic condition or a problem with a part of the brain called the hypothalamus
  • People who have been diagnosed by a doctor with polycystic ovary syndrome (PCOS)
  • People who are pregnant or planning to become pregnant
  • People currently using supplemental hormones
  • People who have been diagnosed with an eating disorder such as anorexia nervosa, bulimia, or binge eating disorder
  • People who have Type 1 or Type 2 diabetes
  • People currently being treated with growth hormones
  • People with a thyroid condition or problem
  • People who have had cancer within the last 10 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Justin Ryder, PhD, Ann & Robert H Lurie Children's Hospital of Chicago

Phone: 3148826838

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Registry
ClinicalTrials.gov
Start date
26 August 2023
Est. completion
1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in fat mass regain after initial weight loss with meal replacement therapy (MRT); Change in ghrelin; Change in gastric inhibitory polypeptide

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov